BioSig Technologies Inc  - BSGM OTCQB  - Trading Alert

ALERT - This medical device stock has roared to life over the past 90 days advancing more than 75%  spiking to $2.00 on March 22 . We expect these shares to test its 52 week high of $2.20 before moving to test its $3.00 resistance.

We feel that this stock should be considered on any pullback from current levels . On Line Brokers

BioSig Technologies Announces Collaboration with Mayo Clinic Physician Team - Corrected Version

Agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future technologies

Minneapolis, MN, March 23, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed an agreement with a team of Mayo Clinic physicians.  This new, expanded collaboration builds upon the work realized under the Advanced Clinical Research Program that was signed with Mayo Clinic in March 2016.

BioSig intends to work closely with Samuel Asirvatham, M.D. and K. L. Venkatachalam, M.D., cardiac electrophysiologists at Mayo Clinic, to develop advanced clinical features and applications for its PURE EP System as well as to leverage the company’s core competency in physiologic signal processing to develop future technologies.  Drs. Asirvatham and Venkatachalam are expected to contribute know-how, intellectual property and clinical support to the partnership. The company expects joint patent filings to come out of the relationship.

Kenneth L. Londoner, Executive Chairman and Founder commented, “We are pleased to strengthen and broaden our relationship and to grow our innovation capabilities and deliver superior medical technology.”

Greg Cash, President and CEO added “Our experience working with Drs. Asirvatham and Venkatachalam has been outstanding and has resulted in three peer reviewed publications to-date.  Adding innovation and intellectual property to the equation should raise this collaboration to a whole new level, with the hope of better diagnosis and treatment of complex arrhythmias in many patients.”

About BioSig Technologies

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace ( Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.

BioSig’s technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

Data from the 2016 HRI Global Opportunities in Medical Devices & Diagnostics report shows the global Electrophysiology (EP) market revenues is expected to grow nearly 10% annually, from currently $4 billion to approximately $6 billion by 2020 with accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020. Procedure growth in the United States alone is projected at an 11.0% annual rate, from 250,000 in 2015 to 422,000 in 2020; accompanied by an 11.7% growth in revenues, from $1.85 billion in 2015 to $3.220 billion in 2020. 

BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP System. The company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center, and has performed pre-clinical studies at Mayo Clinic in Minnesota and Mount Sinai Hospital in NY. The company continues to perform research and development studies in the form of an Advanced Research Program at Mayo Clinic which began in June 2016. Other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute and UH Case Medical Center in Cleveland also play an important role in the PURE EP technology.

Forward and Cautionary Statement - Disclaimer

 is a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. 

A complete disclaimer can be viewed